Studies were designed to investigate the mechanisms underlying the augmentation by angiotensin I converting enzyme (ACE) inhibitors of the endothelium-dependent relaxations evoked by bradykinin. Isometric tension, tissue levels of cGMP, and transmembrane potential were measured in isolated canine coronary arteries as indications of the respective contribution of nitric oxide and endothelium-derived hyperpolarizing factor. In rings of coronary artery with endothelium, relaxations to bradykinin were potentiated by the ACE inhibitors cilazaprilat and perindoprilat. NG-Nitro-L-arginine (NLA), a nitric oxide synthase inhibitor, impaired relaxations to bradykinin. But the presence of ACE inhibitors partially restored this activity. Bradykinin stimulated the production of cGMP, and this was enhanced significantly by ACE inhibitors, indicating an augmented release of nitric oxide. NLA abolished the increase induced by bradykinin irrespective of the presence of ACE inhibitors. Electrophysiological studies revealed that bradykinin elicited an endothelium-dependent hyperpolarization of vascular smooth muscle that was insensitive to NLA and potentiated by ACE inhibitors. The bradykinin-induced hyperpolarization and NLA-resistant relaxations were transient and impaired by potassium depolarization. Thus, production of endothelium-derived hyperpolarizing factor may account for the NLA-resistant relaxations of canine coronary arteries. 
are usually endothelium dependent5'6 and mediated by B2 kinin receptors.7 The endothelium of the arterial wall is a source of vasodilator mediators, including prostacyclin,8 endothelium-derived relaxing factor (which is either nitric oxide9-11 or a nitroso compound12), and an as-yet-unidentified endothelium-derived hyperpolarizing factor.'3"14 ACE inhibitors augmnent the hemodynamic vasodilator actions of bradykinin in humans,15 and we have shown previously that endothelium-dependent relaxations to bradykinin in isolated canine arteries are potentiated by these compounds. 2'1617 In canine coronary arteries, nitric oxide appears to be tors of these relaxations, experiments were designed to assess the contribution of endothelium-derived hyperpolarizing factor to this process. Additionally, the kinin receptor subtype mediating the response was determined. The endothelium-dependent responses were monitored by determination of mechanical activity (to assess the release of endothelium-derived relaxing factors),18 by determination of tissue levels of cGMP (as an index for the production of nitric oxide), '9 and by measurement of electrical transmembrane potential (to assess the production of endothelium-derived hyperpolarizing factor). ' 7.4 (control solution) and cleaned of connective tissue. The coronary arteries were cut into rings (3-4 mm) or transverse strips (2-3 mm, for electrophysiological studies). Special care was taken not to damage the luminal surface of the preparations. In some rings, the endothelium was removed mechanically by inserting the tips of a watchmaker's forceps into the lumen and gently rolling the preparation back and forth over a paper tissue wetted with cold control solution. The effects of the nonsulfhydryl-containing ACE inhibitors perindoprilat17,20
and cilazaprilat'62' were assessed. All the experiments were carried out in the presence of indomethacin (10M ), and some were conducted during depolarization by a 60 mM potassium solution in which NaCl was substituted by equimolar amounts of KCl.
Organ Chamber Experiments
Coronary artery rings were suspended between two stirrups in organ chambers (20 ml) filled with control solution (gassed with 95% 02-5% CO2 and maintained at 37°C). One of the stirrups was anchored inside the organ chamber, and the other was connected to a force transducer (Celaster, Lusignan, France) to record changes in isometric tension. The rings were stretched to the optimal point of their length-active tension relation (8.1 ± 1.2 g) as determined by the contractile response to 60 mM KCl at progressive levels of stretch. The relaxations to bradykinin were observed in rings contracted with prostaglandin F2, ( n=6; Figure 1 ). The concentration-relaxation curves were shifted significantly toward the left by perindoprilat (pIC50, 9.8+±0.1; n=6; Figure 1 ) and cilazaprilat (p1C50, 9 7+0.1; n=6; Figure 1 ).
In the presence of NG-nitro-L-arginine (3 x 10-5 M), the relaxation induced by bradykinin was transient and occurred at high concentrations only (Figures 2 and 3 ). Bradykinin, log (M) 
Bradykinin Degradation
When [1'I-Tyr8]-bradykinin was applied directly to the G-10 SEPHADEX column, the elution profile was characterized by a single peak, and more than 90% of the total radioactivity was eluted in the void volume. Incubation of ["'I-Tyr8]-bradykinin with coronary artery rings for 10 minutes resulted in a reduction in the total radioactivity eluting in the column void volume, and this was paralleled by the appearance of a second included peak of radioactivity ( Figure 9 ). The inclusion of perindoprilat (10 6 M) in incubations of radioactive bradykinin with coronary artery rings eliminated the second included peak of radioactivity, and more than 90% of the total radioactivity applied to the columns was eluted in the void volume.
Discussion
The present study confirms that ACE inhibitors potentiate endothelium-dependent relaxations to bradykinin in the canine coronary artery rings.1617 ACE inhibitors possess unspecific actions that may contribute to their antihypertensive actions.2 For example, the sulfhydryl group of captopril enables this agent to protect The present study demonstrates that ACE inhibition potentiates the production of nonprostanoid endothelium-derived relaxing factors stimulated by bradykinin. The findings reported here may be relevant to the in vivo hemodynamic actions of bradykinin and ACE inhibitors. '5 ACE cleaves bradykinin at the peptide bond between amino acid residues 7 and 81; this would generate a radiolabeled dipeptide when ["'I-Tyr']-bradykinin is used. The elution of the labeled dipeptide, which is a smaller entity, is significantly retarded on a G-10 SEPHADEX column, whereas the nondegraded bradykinin elutes more rapidly in the void volume. Thus, incubation of coronary artery rings with ["'I-Tyr8]-bradykinin yields an elution profile with two peaks; the retarded peak corresponds to the dipeptide. The ACE inhibitor perindoprilat prevented the appearance of the retarded peak and, thus, the degradation of bradykinin. The ability of ACE to degrade bradykinin as well as to generate angiotensin II from angiotensin I is well established.4 A bradykinin-potentiating protein, extracted from the venom of the snake Bothrops jararaca,31 was the prototype for the design of the class of antihypertensive drugs referred to as ACE inhibitors.3'33 Since the potentiation of bradykinin-induced endothelium-dependent responses was identical for cilazaprilat and perindoprilat, as well as for captopril,7 this effect in canine arteries results from the inhibition of ACE.
In the absence of ACE inhibitors, the nitric oxide synthase inhibitor NG-nitro-L-arginine prevents the relaxations to bradykinin. However, high concentrations of bradykinin overcome the antagonism of NG-nitro-Larginine. In the presence of ACE inhibitors, the relaxations of coronary artery rings to bradykinin are resistant to NG-nitro-L-arginine. Addition of either methylene blue6'23 or LY8358324 to NG-nitro-L-arginine did not further inhibit bradykinin-induced relaxation in the presence of ACE inhibitors. Measurements of the levels of cGMP are an indication of nitric oxide production. 19 The present study confirms that the levels of the cyclic nucleotide are greater in rings with as compared with rings without endothelium,23,34 as a result of a basal release of nitric oxide. Perindoprilat when added alone did not affect this parameter in coronary artery rings with or without endothelium. Bradykinin stimulated the production of cGMP in coronary artery rings (with endothelium), and this was enhanced by ACE inhibition. NG-Nitro-L-arginine abolished the effects of both basally released nitric oxide and bradykinin on the levels of cGMP, irrespective of the presence of ACE inhibitors. Thus, it may be concluded that the relaxation to bradykinin in the presence of ACE inhibitors is not mediated exclusively by the cyclic nucleotide since it is not abolished by NG-nitro-L-arginine. This finding had not been reported previously6J6,17 and must be considered when explaining the potentiation by ACE inhibitors of the relaxation to bradykinin.
The present study demonstrates that endotheliumdependent hyperpolarization contributes to the relaxation of canine coronary artery evoked by bradykinin and its potentiation by ACE inhibitors. This conclusion is prompted by the following observations. The relaxations of the canine coronary arteries induced by bradykinin in the presence of NG-nitro-L~arginine are transient, and the addition of an ACE inhibitor elicits a further relaxation. Accordingly, bradykinin evokes a transient hyperpolarization that is enhanced acutely by ACE inhibitors. Furthermore, bradykinin does not provoke endothelium-dependent hyperpolarization in tissues depolarized with potassium. Endothelium-dependent relaxations to bradykinin obtained in tissues contracted with potassium are abolished by N0-nitro-Larginine. In other arteries, endothelium-dependent hyperpolarizations and the associated relaxations are impaired by elevating the extracellular potassium concentration.2935 The transient endothelium-dependent hyperpolarization induced by acetylcholine or bradykinin is consequent to the release of a diffusible factor by the endothelium13,36 and is not due to electrotonic coupling,37 in particular in canine arteries.13 Although in the rat uterine artery nitric oxide can cause hyperpolarization,38 several studies report that endothelium-dependent hyperpolarizations are insensitive to either methylene blue or NG-nitro-L-arginine.2935 Further, in most arteries hyperpolarizations are not mimicked by exogenous nitric oxide39 or cGMP. 40 The present experiments suggest that under control conditions the endothelium-dependent relaxation induced by bradykinin in the canine coronary artery is due to nitric oxide, whereas in the presence of ACE inhibitors both nitric oxide and endothelium-derived hyperpolarizing factor contribute to the response. This change may have resulted 1) from a poor coupling of the B2 receptors to the release of endothelium-derived hyperpolarizing factor or 2) from a recruitment of kinin receptors that would have a low affinity toward the agonist.26 For example, in the rabbit saphenous artery acetylcholine stimulates the production of nitric oxide via M2 cholinergic muscarinic receptors, whereas endo- bradykinin is competitive, as demonstrated by the Arunlakshana and Schild analysis.7 The pA2 value is typical of B2 kinin receptors reported previously.7 It has been documented that this antagonist does not affect the responses to bradykinin,7 which may be due to activation of B3 kinin receptors. 42 The B1 kinin receptor antagonist des-Arg9,[Leut]-bradykinin had no effect either in the absence (authors' unpublished observation and Reference 7) or in the presence of NG-nitro-Larginine. However, the relaxations obtained in the presence of N0-nitro-L-arginine were also antagonized by D-Arg[Hyp3,D-Phe ]-bradykinin. This suggests that the augmentation of endothelium-dependent hyperpolarization observed in the presence of ACE inhibitors results from the activation of B2 kinin receptors also. Because the production of both factors is mediated by the same receptor subtype and because a relatively high concentration of bradykinin is necessary to evoke hyperpolarization in the absence of ACE inhibitors, it appears likely that the release of endothelium-derived hyperpolarizing factor is coupled less efficiently to these receptors than the release of nitric oxide.
In some experimental models, kinin receptor antagonists impair the antihypertensive actions43 and the cardioprotective effects of ACE inhibitors.44 ACE inhibitors evoke endothelium-dependent relaxations in freshly isolated canine carotid arteries, which are antagonized by B2 kinin receptor antagonists but are not mimicked by angiotensin II receptor antagonists. 45 This indicates that local kinin-generating systems may contribute to the acute vasodilator actions of ACE inhibitors. The results obtained in the present study suggest that this vasodilatation is mediated conjointly by nitric oxide and endothelium-derived hyperpolarizing factor released by kinins.
